Thermo Fisher Scientific introduces MagMAX Sequential DNA/RNA Kit to Help Advance and Accelerate Hematological Cancer Research 

Thermo Fisher Scientific has introduced the Applied Biosystems™ MagMAX™ Sequential DNA/RNA kit to enable clinical and translational researchers to conduct comprehensive DNA and RNA genomic analysis and streamline detection of genetic abnormalities found in hematological malignancies.  

The MagMAX Sequential DNA/RNA kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications. This integration merges two separate workflows into one sequential process, accommodating up to 15,000 white blood cells per microliter without the need for an additional red blood cell lysis step. By simplifying the workflow and reducing the need for multiple processes, it enhances overall lab productivity and helps reduce costs.  

Research and clinical applications of hematological cancer like leukemia, lymphoma and myeloma is increasingly important, as approximately 10% of new cancer cases each year are hematological, according to the Leukemia & Lymphoma Society. To understand and identify the cancer-causing genetic alterations that cause hematological cancer, researchers need to be able to efficiently isolate nucleic acids from hematological samples. 

“When researching blood cancer, it’s essential for scientists to extract the maximum amount of information from minimal sample volumes. Through this product innovation, we are supporting researchers and clinicians by providing a solution that allows for high-quality sequential isolation of genomic DNA and total RNA from a single blood or bone marrow sample,” said Kevin Lowitz, vice president, sample preparation, Thermo Fisher Scientific. “We’re proud to help streamline comprehensive genomic analysis, helping improve efficiency and preserve precious samples.”  

Key Applications

The product is designed for specialty labs, large health system labs, academic medical centers and pharmaceutical and biotechnology companies developing clinical research in personalized medicine, conducting internal development, clinical research or clinical trials.

Features/Benefits

• Separate DNA and RNA Eluates: Helps eliminate the need for additional steps, including manual RNase treatment to a final total nucleic acid eluate when separate DNA and RNA samples are needed. 
• Increase Productivity: Automation of sequential DNA and RNA isolation provides a streamlined workflow for fast time-to-data with less hands-on time. 
• Scale Workflows to Meet Varying Needs: Enables high-quality nucleic acid isolation, with scalable and flexible sample volume input and throughput. 
• Test Utilization Management: Helps maximize efficiency while preserving precious samples with one streamlined workflow. 
• Compact Packaging: Space-saving design to enable easy storage in various lab settings.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Recent news from Thermo Fisher Scientific